Zanvastro, an antisense oligonucleotide therapy, represents the first independent neurology launch for Ionis Pharmaceuticals, ...
The data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution ...
New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a ...
The success of apazunersen in a Phase 3 trial for Angelman syndrome was a key driver of Ultragenyx’s value, according to William Blair, and the asset’s failure robs the biotech of any meaningful ...
With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of ...
Novartis suspended multiple studies of a CAR T candidate after three patients who received the therapy suffered fatal cases ...
Last month’s FDA advisory committee meetings for therapies developed by Capricor Therapeutics and Replimune effectively ...
With U.S. data science jobs projected to grow 35% over the next decade, a recruiter and talent strategy director discuss the ...
Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate ...
In this episode of Denatured, you’ll hear from Christina Takke, managing partner at V-Bio Ventures and Mariette van der ...
BMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of ...
Roche has tapped Simcere Zaiming for a new T cell engager that could have broad application in B cell–mediated diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results